TY - JOUR
T1 - Digital Inhalers and Remote Patient Monitoring for Asthma
AU - Mosnaim, Giselle S.
AU - Greiwe, Justin
AU - Jariwala, Sunit P.
AU - Pleasants, Roy
AU - Merchant, Rajan
N1 - Funding Information:
Conflicts of interest: G. S. Mosnaim receives current research grant support from GlaxoSmithKline, Novartis, Sanofi-Regeneron, and Teva and has received past research grant support from Astra-Zeneca, Alk-Abelló, and Genentech. J. Greiwe is a speaker and serves on advisory boards for AstraZeneca, Regeneron, and Sanofi Genzyme. S. P. Jariwala has received grant support from the National Institutes of Health, Agency for Healthcare Research and Quality, Stony Wold-Herbert Fund, Patient Centered Outcomes Research Institute, the American Lung Association, Price Family Fund, Genentech, AstraZeneca, SondeHealth, and Einstein Clinical and Translational Science Award/National Center for Advancing Translational Sciences; and has served as a consultant and/or member of a scientific advisory board for Teva and Sanofi. R. Merchant receives research grant support from Propeller Health; serves as a consultant for Sanofi/Genzyme and Propeller Health; and serves as a speaker and advisor for Teva. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
Conflicts of interest: G. S. Mosnaim receives current research grant support from GlaxoSmithKline, Novartis, Sanofi-Regeneron, and Teva and has received past research grant support from Astra-Zeneca , Alk-Abelló , and Genentech . J. Greiwe is a speaker and serves on advisory boards for AstraZeneca, Regeneron, and Sanofi Genzyme. S. P. Jariwala has received grant support from the National Institutes of Health , Agency for Healthcare Research and Quality, Stony Wold-Herbert Fund, Patient Centered Outcomes Research Institute, the American Lung Association, Price Family Fund, Genentech, AstraZeneca, SondeHealth, and Einstein Clinical and Translational Science Award/National Center for Advancing Translational Sciences; and has served as a consultant and/or member of a scientific advisory board for Teva and Sanofi. R. Merchant receives research grant support from Propeller Health; serves as a consultant for Sanofi/Genzyme and Propeller Health; and serves as a speaker and advisor for Teva. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2022 American Academy of Allergy, Asthma & Immunology
PY - 2022/10
Y1 - 2022/10
N2 - Digital inhaler systems, remote patient monitoring, and remote therapeutic monitoring offer great promise as diagnostic tools and therapeutic interventions to improve adherence and inhaler technique for patients with difficult-to-control asthma. In turn, improvements in adherence and inhaler technique may translate into decreasing the need for high side effect treatments such as oral corticosteroids and costly therapies including biologics. Although more clinical trials are needed, studies that use digital inhaler systems to collect objective real-time data on medication-taking behavior via electronic medication monitors and feed this data back to patients on their mobile asthma app, and to health care professionals on the clinician dashboard to counsel patients, show positive outcomes. This article addresses the use of these diagnostic and therapeutic tools in asthma care, how to choose a digital inhaler system, how to teach patients to use the system, strategies for the adoption of these technologies in large health care systems as well as smaller practices, coding and reimbursement, liability concerns, and research gaps.
AB - Digital inhaler systems, remote patient monitoring, and remote therapeutic monitoring offer great promise as diagnostic tools and therapeutic interventions to improve adherence and inhaler technique for patients with difficult-to-control asthma. In turn, improvements in adherence and inhaler technique may translate into decreasing the need for high side effect treatments such as oral corticosteroids and costly therapies including biologics. Although more clinical trials are needed, studies that use digital inhaler systems to collect objective real-time data on medication-taking behavior via electronic medication monitors and feed this data back to patients on their mobile asthma app, and to health care professionals on the clinician dashboard to counsel patients, show positive outcomes. This article addresses the use of these diagnostic and therapeutic tools in asthma care, how to choose a digital inhaler system, how to teach patients to use the system, strategies for the adoption of these technologies in large health care systems as well as smaller practices, coding and reimbursement, liability concerns, and research gaps.
KW - Adherence
KW - Asthma
KW - Dashboard
KW - Digital inhaler systems
KW - Electronic medication monitoring
KW - Inhaler technique
KW - Remote patient monitoring
KW - Remote therapeutic monitoring
UR - http://www.scopus.com/inward/record.url?scp=85135360161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135360161&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2022.06.026
DO - 10.1016/j.jaip.2022.06.026
M3 - Article
C2 - 35779779
AN - SCOPUS:85135360161
SN - 2213-2198
VL - 10
SP - 2525
EP - 2533
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 10
ER -